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Abstract 
Neuropsychiatric symptoms occur commonly in patients with systemic lupus 
erythematosus (SLE), but they are not always due to active disease. It is crucial to 
identify cases that are due to active SLE so that appropriate treatment can be 
instituted. There is no single serological or imaging test that distinguishes active 
neuropsychiatric SLE (NPSLE) from NP manifestations caused by other factors such 
as infection. Most patients with NPSLE have generalised features of disease activity. 
Raised anti-dsDNA and low C3 complement levels are often seen, but are not an 
invariable guide. The presence of antiphospholipid antibodies is more suggestive of 
thrombotic than inflammatory causation.  A number of other autoantibody tests have 
been proposed as biomarkers for NPSLE, but results in clinical studies have been 
inconsistent and none has so far entered routine clinical practice. Cerebrospinal fluid 
features and magnetic resonance imaging (MRI) appearances are non-specific in 
NPSLE, but are useful in excluding other causes of NP symptoms. Newer MRI 
sequences show promise for distinguishing new NPSLE activity from previous 
damage and recent research suggests these may correlate with changes in cognitive 
function in patients with SLE. However, formal cognitive testing is seldom carried out 
in the acute setting. 
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Introduction 
Neuropsychiatric (NP) events in SLE can affect between 21-95% of patients with 
SLE (1). This wide range of prevalence figures across different studies arises from 
the fact that manifestations recognised as NPSLE are very varied. The American 
College of Rheumatology (ACR) has defined 19 NPSLE syndromes (2).   NPSLE 
can vary from symptoms such as mild mood disorder to psychosis or status 
epilepticus. NP involvement is rarely a presenting feature of SLE (3), but is 
associated with lower patient-reported health related quality of life indices (1, 4). 
NPSLE accounts for up to 19% of deaths in patients with SLE (5). Thus it is very 
important to be able to identify which NP symptoms in a patient with SLE are due to 
active disease and require treatment with corticosteroids/immunosuppression. 
 
Current tools for analysis of NPSLE 
 
Clinical Assessment 
Between 40-50% of NP events occur in the presence of generalised active SLE (3). 
It is rare for NPSLE to occur in the absence of any other form of disease activity. 
Global disease activity measured by SLEDAI-2K was found to be significantly higher 
in patients with NPSLE than patients with SLE (6), mainly in patients with central 
nervous system (CNS) NPSLE or diffuse NP syndromes.   
 Serum analysis 
The typical picture of elevated erythrocyte sedimentation rate (ESR) with normal 
CRP levels characteristic of active SLE may also be seen in NPSLE (7), and the 
additional presence of raised anti-double stranded DNA (anti-dsDNA) and reduced 
complement (8) is a strong pointer to active disease. However, a normal ESR or 
negative serology does not exclude CNS lupus and raised inflammatory markers can 
occur in other conditions causing NP symptoms in patients with SLE, such as CNS 
infection. 
 
Antibodies play an important role in disease pathogenesis in SLE (9). It has been 
postulated that NPSLE may be a result of dysregulation of the blood brain barrier 
(10). Currently, the only autoantibody tests in routine clinical use for evaluating 
NPSLE are anti-dsDNA and antiphospholipid antibodies. 
 
High titres of double stranded DNA antibodies are seen in 70% of patients with 
active NPSLE symptoms (7), and support a diagnosis of globally active SLE, but 
they are not specific for NPSLE syndromes.  
 
Antiphospholipid antibodies (aPL) measured in clinical practice encompass 
anticardiolipin (aCL), lupus anticoagulant (LAC) and anti-beta2glycoprotein I (anti- 
β2GPI). Their association with both focal and diffuse presentations of NPSLE is well 
studied, including stroke, seizures, epilepsy, migraine headaches as well as 
cognitive impairment (11, 12). aCL has also been found to be associated with 
cognitive impairment (13), but this association is not upheld in all studies (14). 
However, overall aCL is more strongly associated with NPSLE (11, 15, 16) when 
compared with LAC, whereas LAC has the stronger association with cerebrovascular 
disease, especially stroke or sinus thrombosis (17). aPL are also associated with 
increased risk of transverse myelopathy, chorea, seizure and migrainous headache 
(18).  
 
There is a relationship between aPL antibodies and cognitive impairment. In one 
study cognitive deficits were three times more common in APS and SLE with aPL 
than healthy controls (80%,75% and 16% respectively) (19).  
 
It is important, however, to note that positive tests for aPL are typically not helpful in 
decisions about immunosuppression. They may instead inform decisions regarding 
whether to anticoagulate the patient.  
 
CSF Analysis 
30-90% of patients with active NPSLE are found to have mild non-specific 
abnormalities in their CSF, typically modestly raised WCC (usually a lymphocytosis) 
and elevated protein with normal glucose (7). In a study of 41 patients (7), abnormal 
CSF results were associated with a poorer outcome, with higher morbidity and 
mortality.  
Aseptic meningitis is rare, accounting for up to 4.3 % of NPSLE presentations (20). 
CSF often demonstrates normal or only mildly low glucose and a lower lymphocyte 
count than in viral meningitis. Abnormal CSF is indicative of a worse outcome. 
Oligoclonal bands are found in 15-85% of patients with SLE, in the absence of other 
supporting evidence for multiple sclerosis. 
 
Overall, lumbar puncture is not absolutely necessary in the management of possible 
NPSLE, especially with clear signs of SLE activity (raised anti-dsDNA and low C3). 
However, CSF analysis may be invaluable where the differential diagnosis between 
NPSLE and infection is unclear. 
 
Cerebral Imaging 
Computer-assisted Tomography (CT). CT is not a reliable tool in NPSLE, its main 
use is to enable differentiation from infarcts and haemorrhages during an acute 
presentation of stroke. 
  
Magnetic Resonance Imaging. MRI remains the imaging modality of choice. It is a 
very sensitive tool for picking up inflammatory or ischaemic changes secondary to 
SLE, and to exclude alternative diagnoses. There is no robust evidence supporting 
particular abnormalities on MRI that are specific for NPSLE (21). Abnormal scans 
tend to be associated with focal, and normal scans with more diffuse, neurological 
presentations (7). The most common cerebral MRI abnormalities described in 
patients with SLE are white-matter hyperintensities (8-75% of patients) in a 
predominantly fronto-parietal distribution (22, 23), and cerebral atrophy (9-67%) (24, 
25). Focal lesions or non-specific changes seen on MRI (including vascular infarcts) 
do not reliably correlate with disease severity (26).  MRI techniques able to detect 
tissue microstructural changes include diffusion tensor imaging (DTI) and 
magnetization transfer imaging (MTI) and appear to show some correlation with the 
severity of NPSLE (26).  
 
In a retrospective study, 40% of NPSLE patients had completely normal cerebral 
MRI scans (21, 24). The most frequent abnormality identified in the remaining 60% 
was microangiopathy, predominantly in the frontal and parieto-occipital regions, 
which in turn correlated with cognitive dysfunction, low CH50 and LAC. 13.7% of 
NPSLE had evidence of microbleeds and 11.1% lacunar infarcts, again associated 
with LAC.  
Large vessel disease is estimated to affect about 13% of NPSLE presentations (21) 
with 50% of these patients having more than one large-vessel infarct. Primary 
cerebral vasculitis (both focal or widespread) on MRI remains rare, was estimated to 
affect 6.5% of SLE patients having MRIs (21), and was associated with markers of 
global disease activity, most specifically low complement.  
 
Cognitive testing 
Since cognitive testing is perceived to be time consuming and often not immediately 
available, it is seldom requested in suspected acute NPSLE. However, studies have 
demonstrated cognitive dysfunction in 20-80% of patients with SLE across a broad 
range of cognitive domains including; attention, executive function and speed of 
processing, learning and memory, visuospatial skills and psychomotor function (27). 
The most commonly reported changes were in learning and attention with studies 
attributing some of these changes to alterations in subcortical white matter and 
fronto-parietal function (27, 28).  
 
One of the main challenges of cognitive testing in these patients is the interaction 
with increasing age, major depression and steroid use (29). Cognitive testing must 
be interpreted in the context of these and other factors which are likely to affect 
performance.  
 
Potential new serum assays for analysis of NPSLE 
 
Anti-ribosomal P antibodies (anti-P) 
A positive anti-P test (30) shows high specificity for SLE, occurs in 15-20% of 
patients with SLE and high titres may be a marker of active disease(31). Elevated 
anti-P was reported to have a strong association, both in serum and CSF, with lupus 
related psychosis (17, 30, 32, 33). Other studies claimed that high anti-P levels were 
very specific for depression and psychosis, especially when present with anti-β2GPI 
(34). Detection of anti-P in the serum can predate the first episode of psychosis by a 
median of 5.69 years (17).  However, a large international meta-analysis (35) with 
1537 patients did not support the use of anti-P either as a marker of NPSLE as a 
whole or for psychosis or mood disorders.  
 Anti-N-methyl-D-aspartate receptor subtype 2 (anti-NR2) antibodies 
Anti-dsDNA antibodies  cross-react with NR2 receptors in the CNS, suggesting a 
potential role in NPSLE (36). Originally high anti-NR2 was thought to be strongly 
associated with depression, short term memory and learning impairment (37-39), but 
these findings failed to be reproduced despite multiple attempts (29). 
 
Although titres of anti-NR2 were initially thought to be associated with significantly 
lower performance scores in sustained attention and executive function in SLE, they 
are not consistently found to be a reliable biomarker for cognitive dysfunction (29, 40) 
and this association did not hold up in a large meta-analysis (34). 
 
Anti-NR2 antibodies are found in the CSF of a third of SLE patients (41), which is 
higher than other autoimmune diseases. During acute CNS presentations or septic 
meningitis, CSF anti-NR2 titres increase more than serum levels (42). However, anti-




Anti-GABARB1b and anti-GABARB2 antibodies were found exclusively in SLE (but only 
in 15% of patients) in one small study (43). There was also a significant association 
between the titres and SLEDAI scores.  
 Anti-endothelial antibodies are found in the serum of 17-75% of patients with SLE 
(44), and are associated with psychiatric disorders in NPSLE, most specifically 
psychosis and depression.  
 
Anti-neuronal antibodies. A recent large meta-analysis (34) of 41 trials found 
significant increases in the serum titres of aCL, LAC, aPL, anti-P antibodies and anti-
neuronal antibodies in patients with NP-SLE when compared to patients with SLE, 
but not NPSLE. In CSF, only anti-neuronal antibody titres were significantly 
increased in patients with NPSLE.  
 
Nitrated Nucleosome levels (NN) 
Both nucleosome levels and overall level of serum protein nitration are elevated in 
patients with active SLE. Thus Croca et al (45) developed a capture ELISA to 
measure NN levels. Serum NN was significantly higher in patients with SLE than in 
healthy people or in patients with other autoimmune diseases. Serum NN titres were 
twice as high in patients with NPSLE flares than in those without NPSLE, but this 
was a small study in only 49 patients and the data have yet to be confirmed. 
 
Potential new imaging techniques for analysis of NPSLE 
Newer MRI sequences such as diffusion weighted images (DWI) and apparent 
diffusion coefficient (ADC) may be helpful in diagnosis and prognosis.  When 
assessing for posterior reversible encephalopathy syndrome, vasogenic oedema 
(which carries a better prognosis) is identified with hypointensity or isointensity on 
DWI and hyperintensity on ADC. Conversely, hyperintensity on DWI and 
hypointensity on ADC are associated with irreversible outcomes (46). 
Novel MRI techniques able to detect tissue microstructural changes, including 
diffusion tensor imaging (DTI) and magnetization transfer imaging/ magnetisation 
transfer spectroscopy, appear to show some correlation with changes seen in 
NPSLE (26). 
Magnetic resonance spectroscopy (MRS) measures cell-specific metabolites, and 
has been correlated with cognitive dysfunction in NPSLE (47). Recently published 
data combines diffusion weighted imaging techniques with MRS (DW-MRS) to allow 
examination of cell and microstructural changes (26). Relatively specific glial 
changes were shown as a marker of previous NPSLE, but patients with active 
NPSLE were not included. This technique may be incorporated with other markers of 
microstructural damage (DTI, MTI and Susceptibility weighted imaging) to aid in the 
diagnostic process. 
 
Functional MRI (fMRI) 
fMRI has demonstrated that patients with SLE may maintain cognitive performance 
through compensatory recruitment of regions where function is preserved. The 
commonest finding is increased signal in regions involved in working memory and 
executive function, mainly fusiform gyrus, prefrontal cortex, parietal regions, 
supplementary motor area and caudate body (48, 49), when compared to healthy 
controls.  
 
It may be possible to use fMRI to distinguish between acute presentations of NPSLE, 
and more chronic disease, by increased resting state functional connectivity in the 
fronto-parietal cortex in the former, and decreased functional connectivity in the latter 
[58]. However, most studies have only included small numbers of SLE patients. No 
correlation has been reported between increased signal on fMRI and disease activity 
measured through serum biomarkers (28, 50). The most reproducible finding in SLE 
is lack of effective integration of functional brain regions during tasks. 
 
There is altered cerebral blood flow (CBF) on fMRI in NPSLE, with abnormal CBF 
being seen in diffuse and focal NPSLE in a regional distribution. This has also been 
shown to normalise with resolution of symptoms (51).  
 
PET/SPECT 
PET-CT and MR spectroscopy were found to have 100% sensitivity in active NPSLE, 
but specificity is low compared to MRI (52).  
PET and SPECT scans show non-specific changes in NPSLE. However they can 
detect subclinical CNS involvement and reveal irregularities in patients with cerebral 
involvement, buts normal MRI scans (53).  
 
Conclusion 
There are no specific individual serological, CSF or neuroimaging findings that 
enable a definite diagnosis of NPSLE to be made. However, by integrating the 
results of clinical and serological analysis together with imaging one can ascertain 
the likelihood that the patient’s clinical presentation is related to active NPSLE rather 
than other causes such as infection. Cognitive testing and neurophysiology are not 
often required in the acute phase of NPSLE, but may be more useful in detecting 
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